Waters Corporation

Waters Corporation

WAT
Waters CorporationUS flagNew York Stock Exchange
368.98
USD
-9.21
- -
24.05BMarket Cap
Waters Corporation
WAT
(New York Stock Exchange)

Recent

price

368.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
17.79
20.38
20.99
22.29
23.58
24.8
26.83
28.94
31.43
35.59
38.09
45.24
49.54
50.04
49.86
53.19
57.85
Revenue per Share
4.13
4.77
5.25
5.27
5.12
5.7
6.46
0.25
7.71
8.76
8.4
11.25
11.8
10.87
10.75
10.8
6.89
Basic EPS, GAAP
4.28
4.54
3.92
4.29
4.81
5.71
6.78
7.61
6.6
7.09
9.95
9.4
7.14
7.48
10.44
9.07
4.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
28.36
33.61
40.01
46.41
52.11
59.09
66.68
67.76
77.89
97.43
114.5
126.71
141.87
154.93
165.01
175.32
158.95
Book Value per Share
6.45
8.12
10.59
13.74
15.53
18.02
21.57
20.62
12.53
-12.02
-7.58
-5.08
-2.55
-13.28
-0.59
11.14
-42.97
Tangible Book Value per Share
92
91
88
85
84
82
81
80
77
68
62
62
60
59
59
60
65
Basic Weighted Avg Shares
1,643
1,851
1,844
1,904
1,989
2,042
2,167
2,309
2,420
2,407
2,365
2,786
2,972
2,956
2,958
3,165
3,771
Sales/Revenue/Turnover
27.38
28.55
28.15
27.17
26.81
28.17
29
29.38
30.55
29.44
27.63
29.68
29.72
27.66
28.32
25.36
16.01
Operating Margin (%)
63
66
69
80
94
90
96
106
108
105
125
132
130
166
192
206
363
Depreciation Expense
382
433
461
450
432
469
522
20
594
592
522
693
708
642
638
643
449
Net Income, GAAP
12.81
14.98
5.37
8.18
12.05
13.45
13.1
96.83
12.95
12.69
14.62
14.06
15.53
12.77
15.5
14.87
14.26
Effective Tax Rate (%)
23.23
23.39
25.03
23.63
21.7
22.97
24.06
0.88
24.54
24.61
22.05
24.87
23.81
21.72
21.56
20.3
11.91
Profit Margin (%)
1,201
1,340
1,753
2,069
2,237
2,649
3,115
3,664
2,214
721
596
948
978
963
879
908
1,791
Working Capital
700
700
1,045
1,190
1,237
1,493
1,702
1,898
1,148
1,648
1,275
1,573
1,587
2,364
1,677
1,000
5,157
LT Debt
1,069
1,227
1,467
1,763
1,895
2,059
2,302
2,234
1,567
-216
232
368
504
1,150
1,829
2,561
15,292
Total Equity
23.48
22.11
19.98
16.37
14.48
14
13.85
0.51
18.31
28.53
33.29
37.76
34.68
23.86
19.22
17.63
4.22
Return on Invested Capital (%)
12.59
12.16
11.17
9.57
8.28
8.08
8.15
0.3
8.74
8.18
6.66
8.14
7.65
6.69
6.18
5.99
3.93
Return on Capital (%)
15.72
15.26
14.05
12.03
10.33
10.13
10.17
0.38
10.41
9.41
7.61
9.29
8.68
7.27
6.73
6.36
4.43
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
488
491
413
LT Borrowings
947
947
4,855
LT Finance Leases
50
53
302
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
98
Market Capitalization
17,829
22,603
19,411

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,919
2,148
4,064
Cash, Cash Equivalents & STI
459
588
462
Accounts Receivable, Net
749
829
1,753
Inventories
573
572
1,496
Total Current Liabilities
1,251
1,239
2,273
Payables & Accruals
184
152
671
ST Debt
488
491
413
Deferred Revenue
301
267
520

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.95%
64.53%
40.07%
Free Cash Flow
3.25%
-0.37%
-12.88%
Net Income, GAAP
275.22%
5.16%
0.75%
Sales/Revenue/Turnover
4.62%
6.2%
6.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
637
709
740
873
2,958
2025
662
771
800
932
3,165
2026
1,267
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.73
2.41
2.72
3.9
10.75
2025
2.04
2.47
2.5
3.78
10.8
2026
-0.88
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Waters Corporation (NYSE: WAT), founded in 1958 and headquartered in Milford, Massachusetts, develops, manufactures, and markets analytical instruments, chromatography columns, and other consumables for the life sciences, pharmaceutical, biopharmaceutical, chemical, food, environmental, and clinical diagnostics industries worldwide. The company offers high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems such as the ACQUITY Premier and Alliance iS series; mass spectrometry instruments including the Xevo G3 QTof, Xevo TQ Absolute, SELECT SERIES MRT, and BioAccord LC-MS; gel permeation and size exclusion chromatography solutions; thermal analysis and rheology products through its TA Instruments division; light-scattering devices from Wyatt Technology; software platforms like Empower and waters_connect for data management and compliance; and related consumables, columns, detectors, and accessories used in drug discovery, development, manufacturing, food safety testing, environmental monitoring, and materials science applications across more than 100 countries with 12 manufacturing facilities and operations in 35 countries. Recent developments include the 2025 acquisition of Halo Labs to expand its biological analysis portfolio for advanced characterization in drug development; the July 2025 agreement to combine with BD's Biosciences and Diagnostic Solutions business in a $17.5 billion all-stock merger creating a leader in regulated life science and high-volume diagnostics testing; and the 2023 acquisition of Wyatt Technology enhancing its capabilities in macromolecular characterization and complex mixture analysis.

Company News

APIChatGPT
  • PitchBook Named Best Alternative Data Provider in Waters Technology Rankings 2026

  • Waters Corporation Is Getting Awfully Pricey

  • Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call

  • IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine

  • Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis

  • Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis

  • Why Is Waters (WAT) Up 8.7% Since Last Earnings Report?

  • Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

  • Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics

  • Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics

  • Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research

  • Carnival: Calm Waters Despite Fuel Price Headwinds

  • Waters Corporation to Present at the Jefferies Global Healthcare Conference

  • Understanding Waters (WAT) Reliance on International Revenue

  • WAT Q1 Earnings Beat Estimates, BD Acquisition Aids Revenues

  • Conrad Industries Is Worth The Volatile Waters The Industry Faces

  • Waters Corporation (WAT) Q1 2026 Earnings Call Transcript

  • Waters raises annual profit forecast as biosciences unit drives growth

  • Waters (WAT) Beats Q1 Earnings and Revenue Estimates

  • Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results